- Home
- NEPH vs BUUU Comparison
NEPH vs BUUU Comparison
Compare NEPH & BUUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- BUUU
- Stock Information
- Founded
- NEPH 1997
- BUUU 2017
- Country
- NEPH United States
- BUUU Hong Kong
- Employees
- NEPH N/A
- BUUU N/A
- Industry
- NEPH Medical/Dental Instruments
- BUUU Services-Misc. Amusement & Recreation
- Sector
- NEPH Health Care
- BUUU Consumer Discretionary
- Exchange
- NEPH Nasdaq
- BUUU Nasdaq
- Market Cap
- NEPH 57.2M
- BUUU 68.1M
- IPO Year
- NEPH 2004
- BUUU 2025
- Fundamental
- Price
- NEPH $5.18
- BUUU $8.10
- Analyst Decision
- NEPH Strong Buy
- BUUU
- Analyst Count
- NEPH 2
- BUUU 0
- Target Price
- NEPH $5.50
- BUUU N/A
- AVG Volume (30 Days)
- NEPH 79.5K
- BUUU 12.6K
- Earning Date
- NEPH 11-05-2025
- BUUU 11-15-2025
- Dividend Yield
- NEPH N/A
- BUUU N/A
- EPS Growth
- NEPH N/A
- BUUU N/A
- EPS
- NEPH 0.12
- BUUU 0.04
- Revenue
- NEPH $16,684,000.00
- BUUU $5,754,120.00
- Revenue This Year
- NEPH $24.38
- BUUU N/A
- Revenue Next Year
- NEPH $10.16
- BUUU N/A
- P/E Ratio
- NEPH $43.88
- BUUU $209.65
- Revenue Growth
- NEPH 21.16
- BUUU 64.23
- 52 Week Low
- NEPH $1.36
- BUUU $3.67
- 52 Week High
- NEPH $5.98
- BUUU $9.50
- Technical
- Relative Strength Index (RSI)
- NEPH 54.89
- BUUU N/A
- Support Level
- NEPH $4.52
- BUUU N/A
- Resistance Level
- NEPH $5.38
- BUUU N/A
- Average True Range (ATR)
- NEPH 0.48
- BUUU 0.00
- MACD
- NEPH -0.05
- BUUU 0.00
- Stochastic Oscillator
- NEPH 45.21
- BUUU 0.00
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.